Javascript must be enabled to continue!
PMON322 Gigantism in 13-Year-Old Male With Pituitary Tumor
View through CrossRef
Abstract
Background
Pituitary gigantism is caused by excess growth hormone [GH] secretion from the pituitary gland when the growth plates are open leading to excessive linear growth and tall stature in the pediatric population. It is extremely rare with a reported incidence of 8 cases per million person-years.
Clinical Case
The patient is a 13-year-old male who presented with concerns of accelerated growth rate and tall stature. His father noticed the patient's tall stature when he passed his own height the last year. The patient was seen by his PCP who referred the family to pediatric endocrinology. His symptoms included snoring and bi-weekly headaches, but no vision changes. Review of his growth charts showed linear growth tracking at greater than the 95th percentile since the age of 9 years. His clinical features included large hands, large feet, prominent jaw, testicular volume >25 ml, tall stature [Ht > 99%, Z= +4.59 SD]. The patient's mid-parental height is 69.1 inches [175.5 cm] and the patient measured 76.6 inches [194.5 cm]. His predicted height was 7 feet 1.5 inches [217.2 cm] based on his bone age. His clinical features were strongly concerning for Gigantism.
Initial labs showed IGF-1 of 924 ng/mL [168–576], prolactin of 20.1 ng/mL [2.8–11.0], and IGF-BP3 8.7 mg/L [3.1–9.5]. Cortisol, ACTH, TSH, FT4, LH, FSH, Testosterone were within normal limits. Bone age was concordant with chronological age. MRI showed enlarged pituitary gland measuring 1.3 cm in height, suspicious for macroadenoma. Cardiac evaluation including echocardiogram came back normal. GH suppression test resulted in a 2-hour GH level of 27.3 ng/mL [<1] and he was diagnosed with Gigantism due to GH-secreting pituitary tumor. The parents decided to consult neurosurgery team at a different facility, where transsphenoidal resection of the pituitary tumor was performed. He did not develop any postoperative complications, including Diabetes insipidus or any pituitary hormone deficiencies, and was discharged home shortly after. Follow-up MRI of the pituitary showed no evidence of residual tumor. Pathology of the macroadenoma expressed GH and prolactin on immunohistochemical stains and was negative for TSH, LH/FSH, and ACTH. Genetic studies obtained were negative, lowering the likelihood of inherited predisposition to endocrine neoplasms. The patient has remained well post-operatively and has been able to continue school and play basketball without issues.
Conclusion
Pituitary gigantism occurs in the pediatric population prior to skeletal epiphyseal closure and is caused by GH excess. Initial screening tests should evaluate for pituitary function including IGF-1 and prolactin levels. The gold standard for diagnosing GH excess is the GH suppression test. Even though rare, it is important for clinicians to keep a high level of suspicion for quick recognition and management of overgrowth syndromes.
Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.
The Endocrine Society
Title: PMON322 Gigantism in 13-Year-Old Male With Pituitary Tumor
Description:
Abstract
Background
Pituitary gigantism is caused by excess growth hormone [GH] secretion from the pituitary gland when the growth plates are open leading to excessive linear growth and tall stature in the pediatric population.
It is extremely rare with a reported incidence of 8 cases per million person-years.
Clinical Case
The patient is a 13-year-old male who presented with concerns of accelerated growth rate and tall stature.
His father noticed the patient's tall stature when he passed his own height the last year.
The patient was seen by his PCP who referred the family to pediatric endocrinology.
His symptoms included snoring and bi-weekly headaches, but no vision changes.
Review of his growth charts showed linear growth tracking at greater than the 95th percentile since the age of 9 years.
His clinical features included large hands, large feet, prominent jaw, testicular volume >25 ml, tall stature [Ht > 99%, Z= +4.
59 SD].
The patient's mid-parental height is 69.
1 inches [175.
5 cm] and the patient measured 76.
6 inches [194.
5 cm].
His predicted height was 7 feet 1.
5 inches [217.
2 cm] based on his bone age.
His clinical features were strongly concerning for Gigantism.
Initial labs showed IGF-1 of 924 ng/mL [168–576], prolactin of 20.
1 ng/mL [2.
8–11.
0], and IGF-BP3 8.
7 mg/L [3.
1–9.
5].
Cortisol, ACTH, TSH, FT4, LH, FSH, Testosterone were within normal limits.
Bone age was concordant with chronological age.
MRI showed enlarged pituitary gland measuring 1.
3 cm in height, suspicious for macroadenoma.
Cardiac evaluation including echocardiogram came back normal.
GH suppression test resulted in a 2-hour GH level of 27.
3 ng/mL [<1] and he was diagnosed with Gigantism due to GH-secreting pituitary tumor.
The parents decided to consult neurosurgery team at a different facility, where transsphenoidal resection of the pituitary tumor was performed.
He did not develop any postoperative complications, including Diabetes insipidus or any pituitary hormone deficiencies, and was discharged home shortly after.
Follow-up MRI of the pituitary showed no evidence of residual tumor.
Pathology of the macroadenoma expressed GH and prolactin on immunohistochemical stains and was negative for TSH, LH/FSH, and ACTH.
Genetic studies obtained were negative, lowering the likelihood of inherited predisposition to endocrine neoplasms.
The patient has remained well post-operatively and has been able to continue school and play basketball without issues.
Conclusion
Pituitary gigantism occurs in the pediatric population prior to skeletal epiphyseal closure and is caused by GH excess.
Initial screening tests should evaluate for pituitary function including IGF-1 and prolactin levels.
The gold standard for diagnosing GH excess is the GH suppression test.
Even though rare, it is important for clinicians to keep a high level of suspicion for quick recognition and management of overgrowth syndromes.
Presentation: Monday, June 13, 2022 12:30 p.
m.
- 2:30 p.
m.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Etiologies and Clinical Presentation of Gigantism in Algeria
Etiologies and Clinical Presentation of Gigantism in Algeria
<b><i>Background/Aims:</i></b> True gigantism is an exceptional and fascinating pediatric disease. Our aim in this study was to describe the different etiol...
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults
GH secretion was reevaluated after completion of GH treatment at a mean age of 19.2 ± 3.2 yr in 35 young adults with childhood-onset GH deficiency (GHD). The patients were subdivid...
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Giant Sacrococcygeal Teratoma in Infant: Systematic Review
Abstract
Introduction
Sacrococcygeal teratoma (SCT) is a rare embryonal tumor that occurs in the sacrococcygeal region, with an incidence of about 1 in 35,000 to 40,000 live births...
[RETRACTED] Gro-X Male Enhancement | Safely Grow Your Size, Sex Drive v1
[RETRACTED] Gro-X Male Enhancement | Safely Grow Your Size, Sex Drive v1
[RETRACTED]Gro-X Male Enhancement Reviews - Is It Worth the Money? Scam or Legit? Gro-X Male Enhancement Male health is very important, especially for a couple. Low sperm count an...
Molecular Genetics in Acromegaly
Molecular Genetics in Acromegaly
Abstract
Pituitary tumours are the most frequent intracranial neoplasms, affecting 1/1000 of the worldwide population. Growth hormone (GH)‐secre...
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
COVID-19 induced hypercoagulability and its impact leading to pituitary apoplexy
I am writing this letter to address an increasingly high-risk but under-explored complication of pituitary apoplexy in patients who have contracted COVID-19. In light of recent res...
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
Data from Senescence Mediates Pituitary Hypoplasia and Restrains Pituitary Tumor Growth
<div>Abstract<p>Understanding factors subserving pituitary cell proliferation enables understanding mechanisms underlying uniquely benign pituitary tumors. Pituitary tu...

